Surgery pp 2037-2059 | Cite as

Melanoma and Other Cutaneous Malignancies

  • Vernon K. Sondak
  • Eric H. Jensen
  • Kim A. Margolin


Cancers of the skin constituted nearly one-half of all cancers diagnosed in 2006, at least 1,000,000 new cases in the United States alone. In fact, the skin is by far the most common primary site for human cancer development. Although skin cancer is often thought of as causing relatively little morbidity and mortality, more than 10,000 deaths were attributed to cutaneous malignancies in the United States in 2005, most (7,770) from malignant melanoma.1 Moreover, both the incidence and mortality of skin cancers are increasing in the United States and throughout most of the world.2,3 Although this chapter focuses primarily on melanoma, a discussion of other cutaneous malignancies is included.


Cutaneous Melanoma Primary Melanoma Isolate Limb Perfusion Excision Margin Nonmelanoma Skin Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Rigel DS. Malignant melanoma: incidence issues and their effect on diagnosis and treatment in the 1990s. Mayo Clin Proc 1997;72:367–371.PubMedCrossRefGoogle Scholar
  3. 3.
    Weinstock MA. Issues in the epidemiology of melanoma. Hematol Oncol Clin N Am 1998;12:681–698.CrossRefGoogle Scholar
  4. 4.
    Wingo PA, Ries LAG, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality. Cancer (Phila) 1998;82:1197–1207.PubMedCrossRefGoogle Scholar
  5. 5.
    Albert VA, Koh HK, Geller AC, Miller DR, Prout MN, Lew RA. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol 1990;23:308–310.PubMedCrossRefGoogle Scholar
  6. 6.
    Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril M-F, Demenais F. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 2004;96:785–795.PubMedGoogle Scholar
  7. 7.
    Rouzaud F, Kadekaro AL, Abdel-Malek ZA, Hearing VJ. MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res 2005;571:133–152.PubMedGoogle Scholar
  8. 8.
    Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and non-cutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer (Phila) 1998;83:1664–1678.PubMedCrossRefGoogle Scholar
  9. 9.
    Katz KA, Jonasch E, Hodi FS, et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 2005;15:77–82.PubMedCrossRefGoogle Scholar
  10. 10.
    Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of California cancer registry data, 1988’93. Cancer Causes Control 1997;8:246–252.PubMedCrossRefGoogle Scholar
  11. 11.
    Byrd KM, Wilson DC, Hoyler SS, Peck GL. Advanced presentation of melanoma in African Americans. J Am Acad Dermatol 2004;50:21–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Halder RM, Bridgeman-Shah S. Skin cancer in African Americans. Cancer (Phila) 1995;75:667–673.PubMedCrossRefGoogle Scholar
  13. 13.
    Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997;73:198–203.PubMedCrossRefGoogle Scholar
  14. 14.
    Langley RGB, Sober AJ. A clinical review of the evidence for the role of ultraviolet radiation in the etiology of cutaneous melanoma. Cancer Invest 1997;15:561–567.PubMedCrossRefGoogle Scholar
  15. 15.
    Berwick M, Armstrong BK, Ben-Porat L, et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005;97:195–199.PubMedGoogle Scholar
  16. 16.
    Tsao H, Sober A. Acquired precursor lesions and markers of increased risk for cutaneous melanoma. In: Balch C, Houghton A, Sober A, Soong S, eds. Cutaneous Melanoma, 4th ed. St. Louis: Quality Medical, 2003:121–134.Google Scholar
  17. 17.
    Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003;139:282–288.PubMedCrossRefGoogle Scholar
  18. 18.
    Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997;277:1439–1444.PubMedCrossRefGoogle Scholar
  19. 19.
    Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003;3:559–570.PubMedCrossRefGoogle Scholar
  20. 20.
    Chudnovsky Y, Khavari PA, Adams AE: Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005;115:813–824.PubMedGoogle Scholar
  21. 21.
    Greene MH, Clark WH Jr, Tucker MA, et al. Acquired precursors of cutaneous malignant melanoma: the familial dysplastic nevus syndrome. N Engl J Med 1985;312:91–97.PubMedGoogle Scholar
  22. 22.
    Lynch HT, Fusaro RM, Pester J, Lynch JF. Familial atypical multiple mole melanoma (FAMMM) syndrome: genetic heterogeneity and malignant melanoma. Br J Cancer 1980;42:58–70.PubMedGoogle Scholar
  23. 23.
    Bale SJ, Dracopoli NC, Tucker MA, et al. Mapping the gene for hereditary cutaneous malignant melanoma: dysplastic nevus to chromosome 1p. N Engl J Med 1989;320:1367–1372.PubMedGoogle Scholar
  24. 24.
    Nancarrow DJ, Mann GJ, Holland EA, et al. Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 1993;53:936–942.PubMedGoogle Scholar
  25. 25.
    Marghoob AA, Schoenbach SP, Kopf AW, Orlow SJ, Nossa R, Bart RS. Large congenital melanocytic nevi and the risk for the development of malignant melanoma: a prospective study. Arch Dermatol 1996;132:170–175.PubMedCrossRefGoogle Scholar
  26. 26.
    Nancarrow D, Platz A, Tucker MA for the Melanoma Genetics Consortium. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894–903.PubMedGoogle Scholar
  27. 27.
    Meyskens FL, Farmer PJ, Anton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. Clin Cancer Res 2004;10:2581–2583.PubMedCrossRefGoogle Scholar
  28. 28.
    Wellbrock C, Ogilvie L, Hedley D, Karasarides M, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004;64:2338–2342.PubMedCrossRefGoogle Scholar
  29. 29.
    Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000;60:1800–1804.PubMedGoogle Scholar
  30. 30.
    Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122:337–341.PubMedCrossRefGoogle Scholar
  31. 31.
    Uribe P, Wistuba II, Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 2003;25:365–370.PubMedCrossRefGoogle Scholar
  32. 32.
    Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003;63:3883–3885.PubMedGoogle Scholar
  34. 34.
    Argenziano G, Soyer HP. Dermoscopy of pigmented skin lesions: a valuable tool for early diagnosis of melanoma. Lancet Oncol 2001;2:443–449.PubMedCrossRefGoogle Scholar
  35. 35.
    Riker AI, Glass F, Perez I, Cruse CW, Messina J, Sondak VK. Cutaneous melanoma: methods of biopsy and definitive surgical excision. Dermatol Ther 2005;18:387–393.PubMedCrossRefGoogle Scholar
  36. 36.
    Saiag P, Bernard M, Beauchet A, Bafounta ML, Bourgault-Villada I, Chagnon S. Ultrasonography using simple diagnostic criteria vs palpation for the detection of regional lymph node metastases of melanoma. Arch Dermatol 2005;141:183–189.PubMedCrossRefGoogle Scholar
  37. 37.
    Starritt EC, Uren RF, Scolyer RA, Quinn MJ, Thompson JF. Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. Ann Surg Oncol 2005;12:18–23.PubMedCrossRefGoogle Scholar
  38. 38.
    Basler GC, Fader DJ, Yahanda A, Sondak VK, Johnson TM. The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes. J Am Acad Dermatol 1997;36:403–408.PubMedCrossRefGoogle Scholar
  39. 39.
    Clark WH, Elder DE, Guerry D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893–1904.PubMedCrossRefGoogle Scholar
  40. 40.
    Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factor analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001;19:3622–3234.PubMedGoogle Scholar
  41. 41.
    Weinstock MA, Morris BT, Lederman JS, Bleicher P, Fitzpatrick TB, Sober AJ. Effect of BANS location on the prognosis of clinical stage I melanoma: new data and meta-analysis. Br J Dermatol 1988;119:559–565.PubMedCrossRefGoogle Scholar
  42. 42.
    Fidler IJ, Ellis LM. Neoplastic angiogenesis. Not all blood vessels are created equal. N Engl J Med 2004;351:215–216.PubMedCrossRefGoogle Scholar
  43. 43.
    Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004;11:247–258.PubMedCrossRefGoogle Scholar
  44. 44.
    Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 2005;32:268–273.PubMedCrossRefGoogle Scholar
  45. 45.
    Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (Phila) 1996;77:1303–1310.PubMedCrossRefGoogle Scholar
  46. 46.
    Tuthill RJ, Unger JM, Liu PY, Flaherty LE, Sondak VK, for the Southwest Oncology Group. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 2002;118:504–511.PubMedCrossRefGoogle Scholar
  47. 47.
    Hawkins WG, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol 2005;12:207–213.PubMedCrossRefGoogle Scholar
  48. 48.
    Balch CM, Soong S, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S, ed. Cutaneous Melanoma, 2nd ed. Philadelphia: Lippincott, 1992:165–187.Google Scholar
  49. 49.
    Ferrari A, Bono A, Baldi M, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics 2005;115:649–654.PubMedCrossRefGoogle Scholar
  50. 50.
    Chao MM, Schwartz JL, Wechsler DS, Thornburg CD, Griffith KA, Williams JA. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer 2004;43:1–8.CrossRefGoogle Scholar
  51. 51.
    Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3cm. N Engl J Med 1988;318:1159–1162.PubMedCrossRefGoogle Scholar
  52. 52.
    Veronesi U, Cascinelli N. Narrow excision (1-cm margin): a safe procedure for thin cutaneous melanoma. Arch Surg 1991;126:438–441.PubMedGoogle Scholar
  53. 53.
    Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996;3:446–452.PubMedCrossRefGoogle Scholar
  54. 54.
    Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1-4mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262–269.PubMedCrossRefGoogle Scholar
  55. 55.
    Thomas JM, Newton-Bishop J, Ahern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004;350:757–766.PubMedCrossRefGoogle Scholar
  56. 56.
    Johnson TM, Sondak VK. Melanoma margins: the importance and need for more evidence-based trials. Arch Dermatol 2004;140:1148–1150.PubMedCrossRefGoogle Scholar
  57. 57.
    Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (0.4 mm) primary melanoma. Ann Surg Oncol 1998;5:322–328.PubMedCrossRefGoogle Scholar
  58. 58.
    Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005;12:1–10.CrossRefGoogle Scholar
  59. 59.
    Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumor-igenicity in thin invasive cutaneous melanoma. J Clin Oncol 2005;23:8048–8056.PubMedCrossRefGoogle Scholar
  60. 60.
    Puleo CA, Messina JL, Riker AI, et al. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control 2005,12:230–235.PubMedGoogle Scholar
  61. 61.
    Balch CM. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 1988;6:163–172.PubMedGoogle Scholar
  62. 62.
    Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255–263.PubMedCrossRefGoogle Scholar
  63. 63.
    Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: preliminary results. Cancer (Phila) 1978;41:948–956.PubMedCrossRefGoogle Scholar
  64. 64.
    Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional node dissection in stage I melanoma of the skin of the lower extremities. Cancer (Phila) 1982;49:2420–2430.PubMedCrossRefGoogle Scholar
  65. 65.
    Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998;351:793–796.PubMedCrossRefGoogle Scholar
  66. 66.
    Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–399.PubMedGoogle Scholar
  67. 67.
    Reintgen DS, Brobeil A. Lymphatic mapping and selective lymphadenectomy as an alternative to elective lymph node dissection in patients with malignant melanoma. Hematol Oncol Clin N Am 1998;12:807–821.CrossRefGoogle Scholar
  68. 68.
    Bostick P, Essner R, Glass E, et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg 1999;134:43–49.PubMedCrossRefGoogle Scholar
  69. 69.
    Evans HL, Krag DN, Teates CD, et al. Lymphoscintigraphy and sentinel node biospy accurately stage melanoma in patients presenting after wide local excision. Ann Surg Oncol 2003;10:416–425.PubMedCrossRefGoogle Scholar
  70. 70.
    Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;6:2253–2260.Google Scholar
  71. 71.
    Morton DL, Thompson JF, Cochran AJ, et al. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in clinical stage I melanoma. J Clin Oncol 2005;23:abstract 7500.Google Scholar
  72. 72.
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation for melanoma. N Engl J Med 2006;355:1307–1317.PubMedCrossRefGoogle Scholar
  73. 73.
    Wang X, Heller R, VanVoorhis N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768–774.PubMedCrossRefGoogle Scholar
  74. 74.
    Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998;280:1410–1415.PubMedCrossRefGoogle Scholar
  75. 75.
    Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006;24:2849–2857.PubMedCrossRefGoogle Scholar
  76. 76.
    Poo-Hwu WJ, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Commission on Cancer stages I-III malignant melanoma. Cancer (Phila) 1999;86:2252–2258.PubMedCrossRefGoogle Scholar
  77. 77.
    Baergen RN, Johnson D, Moore T, Benirschke K. Maternal melanoma metastatic to the placenta. Arch Pathol Lab Med 1997;121:508–511.PubMedGoogle Scholar
  78. 78.
    Mackie RM. Pregnancy and exogenous hormones in patients with cutaneous malignant melanoma. Curr Opin Oncol 1999;11:129–131.PubMedCrossRefGoogle Scholar
  79. 79.
    Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma. COMS report no. 4. Arch Ophthalmol 1997;115(7):886–893.Google Scholar
  80. 80.
    Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 bryachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002;109:2197–2206.PubMedCrossRefGoogle Scholar
  81. 81.
    Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of preenucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10. Am J Ophthalmol 1998;125:779–796.CrossRefGoogle Scholar
  82. 82.
    Cooper JS. The evolution of the role of radiation therapy in the management of mucocutaneous malignant melanoma. Hematol Oncol Clin N Am 1998;12:849–862.CrossRefGoogle Scholar
  83. 83.
    Sondak VK, Wolfe JA. Adjuvant therapy for melanoma. Curr Opin Oncol 1997;9:189–204.PubMedCrossRefGoogle Scholar
  84. 84.
    Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913–916.PubMedGoogle Scholar
  85. 85.
    Quirt IC, Shelley WE, Pater JL, et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1991;9:729–735.PubMedGoogle Scholar
  86. 86.
    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996;14:7–17.PubMedGoogle Scholar
  87. 87.
    Kirkwood JM, Ibrahim JG, Sondak VK, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of inter-group trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444–2458.PubMedGoogle Scholar
  88. 88.
    Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776–2783.PubMedGoogle Scholar
  89. 89.
    Cascinelli N, Bufalino R, Morabito A, MacKie RM. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994;343:913–914.PubMedCrossRefGoogle Scholar
  90. 90.
    Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao M. A pooled analysis of Eastern Cooperative Group and Inter-group trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670–1677.PubMedCrossRefGoogle Scholar
  91. 91.
    Schuchter LM. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? J Clin Oncol 2004;22:7–10.PubMedCrossRefGoogle Scholar
  92. 92.
    Morton DL, Mozzillo N, Thompson JF, et al. An international randomized double blind, phase 3 study of the specific active immunotherapy agent, onamelatucel-L (Canvaxin), compared to placebo as a post-surgical adjuvant in AJCC stage IV melanoma. Ann Surg Oncol 2006;13:5 (abstract).CrossRefGoogle Scholar
  93. 93.
    Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000;18:1614–1621.PubMedGoogle Scholar
  94. 94.
    Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IF A, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115:739–746.PubMedGoogle Scholar
  95. 95.
    Ang KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994;30:795–798.PubMedGoogle Scholar
  96. 96.
    Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol 1995;2:445–449.PubMedCrossRefGoogle Scholar
  97. 97.
    O’Brien CJ, Petersen-Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997;19:589–594.PubMedCrossRefGoogle Scholar
  98. 98.
    Creagan ET, Cupps RE, Ivins JC, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer (Phila) 1978;42:2206–2210.PubMedCrossRefGoogle Scholar
  99. 99.
    Eggermont AM, Brunstein F, Grunhagen D, ten Hagen TL. Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage. Ann Oncol 2004;15(suppl 4):iv-107–iv-112.Google Scholar
  100. 100.
    Taber SW, Polk HC Jr. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. J Surg Oncol 1997;4:440–445.CrossRefGoogle Scholar
  101. 101.
    Lienard D, Ewalenko P, Delmotte J-J, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52–60.PubMedGoogle Scholar
  102. 102.
    Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996;14:479–489.PubMedGoogle Scholar
  103. 103.
    Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004;88(1):1–3.PubMedCrossRefGoogle Scholar
  104. 104.
    Schraffordt Koops H, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase HI trial. J Clin Oncol 1998;16:2906–2912.Google Scholar
  105. 105.
    Margolin K, Atkins MB, Thompson JA, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002;128:214–218.PubMedCrossRefGoogle Scholar
  106. 106.
    Atkins MB, Sosman J, Agarwala S, et al. A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma. Proc Am Soc Clin Oncol 2005;23:723S.Google Scholar
  107. 107.
    Ang KK, Geara FB, Byers RM, Peters LJ. Radiotherapy of melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong S, eds. Cutaneous Melanoma, 3rd ed. St. Louis: Quality Medical, 1998:389–403.Google Scholar
  108. 108.
    Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 2003;22:3113–3122.PubMedCrossRefGoogle Scholar
  109. 109.
    Flaherty KT. New molecular targets in melanoma. Curr Opin Oncol 2004;16:150–154.PubMedCrossRefGoogle Scholar
  110. 110.
    Legha SS. The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 1997;24(1 suppl 4):S24–S31.PubMedGoogle Scholar
  111. 111.
    Atkins MB. Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin N Am 1998;12:877–902.CrossRefGoogle Scholar
  112. 112.
    Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. f Clin Oncol 1999;17:2105–2116.Google Scholar
  113. 113.
    Margolin K. Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction. Cancer (Phila) 2004;101:435–438.PubMedCrossRefGoogle Scholar
  114. 114.
    Sondak VK, Sosman JA. Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®. Semin Cancer Biol 2003;13:409–415.PubMedCrossRefGoogle Scholar
  115. 115.
    Mitchell MS, Harel W, Kempf RA, et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990;8:856–869.PubMedGoogle Scholar
  116. 116.
    Demierre M-F, Swetter SM, Sondak VK. Vaccine therapy of melanoma: an update. Curr Cancer Ther Rev 2005;1:115–125.CrossRefGoogle Scholar
  117. 117.
    Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370–2380.PubMedGoogle Scholar
  118. 118.
    Panelli MC, Wang E, Monsurro W, et al. Overview of melanoma vaccines and promising approaches. Curr Oncol Rep 2004;6:414–420.PubMedCrossRefGoogle Scholar
  119. 119.
    Perales MA, Wolchok JD. Melanoma vaccines. Cancer Invest 2002;20:1012–1026.PubMedCrossRefGoogle Scholar
  120. 120.
    Antonia S, Mule JJ, Weber JS. Current developments of immunotherapy in the clinic. Curr Opin Immunol 2004;16:130–136.PubMedCrossRefGoogle Scholar
  121. 121.
    Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992;327:1649–1662.PubMedGoogle Scholar
  122. 122.
    Halpern AC, Altman JF. Genetic predisposition to skin cancer. Curr Opin Oncol 1999;11:132–138.PubMedCrossRefGoogle Scholar
  123. 123.
    Brooks AD, Heslin MJ, Leung DH, Lewis JJ, Brennan MF. Superficial extremity soft tissue sarcoma: an analysis of prognostic factors. Ann Surg Oncol 1998;5:41–47.PubMedCrossRefGoogle Scholar
  124. 124.
    Swanson NA. Mohs surgery: technique, indications, applications, and the future. Arch Dermatol 1983;119:761–773.PubMedCrossRefGoogle Scholar
  125. 125.
    Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: results of a multi-institutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997;37:600–613.PubMedCrossRefGoogle Scholar
  126. 126.
    Messina JL, Reintgen DS, Cruse CW, et al. Selective lymphadenectomy in patients with Merkel cell (cutaneous neuroendocrine) carcinoma. Ann Surg Oncol 1997;4:389–395.PubMedCrossRefGoogle Scholar
  127. 127.
    Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-Retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235–241.PubMedCrossRefGoogle Scholar
  128. 128.
    Meyskens FL Jr, Kopecky K, Taylor CW, et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma. J Natl Cancer Inst 1995;87:1710–1713.PubMedCrossRefGoogle Scholar
  129. 129.
    Sondak VK, Kopecky KJ, Smith JW II, et al. Is interferon-a detrimental? Results of a Southwest Oncology Group randomized trial of adjuvant human interferon-a versus observation in malignant melanoma. In: Salmon SE, ed. Adjuvant Therapy of Cancer, vol VIII. Philadelphia: Lippincott-Raven, 1997:259–272.Google Scholar
  130. 130.
    Rusciani L, Petraglia S, Alotto M, et al. Postsurgical adjuvant therapy of melanoma: evaluation of a 3-year randomized trial with recombinant interferon-a after 3 and 5 years of follow-up. Cancer (Phila) 1997;79:2354–2360.PubMedCrossRefGoogle Scholar
  131. 131.
    Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998;16:1425–1429.PubMedGoogle Scholar
  132. 132.
    Grob JJ, Dreno B, de la Salmonière P, et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998;351:1905–1910.PubMedCrossRefGoogle Scholar
  133. 133.
    Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004;22:403–415.PubMedCrossRefGoogle Scholar
  134. 134.
    Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003;13:401–417.PubMedCrossRefGoogle Scholar
  135. 135.
    Livingston PO, Wong GYC, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036–1044.PubMedGoogle Scholar
  136. 136.
    Rosenberg SJ, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909–915.PubMedCrossRefGoogle Scholar
  137. 137.
    Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23:2346–2357.Google Scholar
  138. 138.
    Lonchay C, van der Bruggen P, Connerotte T, et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 2004;101(suppl 2):14631–14638.PubMedCrossRefGoogle Scholar
  139. 139.
    Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004;22:4474–4485.PubMedCrossRefGoogle Scholar
  140. 140.
    Klinman D. Immunotherapeutic uses of CpG oligodeoxynucleo-tides. Nat Rev Immunol 2004;4:249–258.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Vernon K. Sondak
    • 1
    • 2
  • Eric H. Jensen
    • 3
  • Kim A. Margolin
    • 4
    • 5
    • 6
  1. 1.Division of Cutaneous OncologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  2. 2.Departments of Surgery and Interdisciplinary OncologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  3. 3.Department of Surgical OncologyH. Lee Moffltt Cancer Center and Research InstituteTampaUSA
  4. 4.Division of Medical Oncology and Therapeutics ResearchCity of Hope National Medical CenterDuarteUSA
  5. 5.Division of Hematology and Hematopoietic Cell TransplantationCity of Hope National Medical CenterDuarteUSA
  6. 6.Medical OncologyCity of Hope National Medical CenterDuarteUSA

Personalised recommendations